Why BGPT?
logo

Science's Data Search Engine

Results grounded in experimental data—not abstracts.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Explanation


    Meta-synthesis map (by study type + bias-risk proxy)
    Across the provided Wang papers, the evidence base is dominated by meta-analyses of human studies (observational and randomized), with additional method/perspective work and one in vitro pharmacogenetics study. Bias risk is not directly reported as a unified RoB metric, so I use a bias-risk proxy derived from each paper’s provided scientific-quality score (lower quality ⇒ higher proxy risk). This proxy is a simplification—see the “What could be misleading” note in the long section.
    Key effect claims and heterogeneity examples include: hysterectomy/oophorectomy vs breast-cancer risk (), BP lowering and stroke/dementia (), smoking cessation and spirometry (), habit-strength interventions (), ozone and diabetes (), and one in vitro CYP3A4 variant metabolism dataset ().



     Long Explanation


    Meta-analysis map: Study type & bias-risk proxy (from provided Wang papers)
    Goal: Compare the provided papers by study type and bias risk.
    Skeptical note: these papers don’t share a single harmonized RoB scale in the provided metadata. So I compute a bias-risk proxy from the provided scientific-quality score (higher quality ⇒ lower proxy risk). This is a model-based proxy, not the same as formal RoB.
    1) Study-type distribution (from provided metadata)
    Study-type mapping (examples): breast-cancer meta-analysis ; BP/stroke/dementia RCT meta-analysis ; ozone/diabetes observational meta-analysis ; CYP3A4 variant kinetics in vitro .
    2) Scientific-quality scores (proxy for bias risk)
    Examples of low score / higher proxy risk: TCM decoction review quality score 3 and MSC commentary score 5 .
    3) Heterogeneity vs quality (where I² was provided)
    Breast-cancer meta-analysis reports substantial I² (e.g., overall I²≈76.5%) . Smoking cessation meta-analysis reports very high I² for some spirometry endpoints (e.g., I²≈97% for FEV1/FVC) .
    4) Bias-risk proxy summary table (from provided metadata)
    Paper (study type) Quality score Proxy bias risk Key bias/uncertainty signals mentioned in provided excerpt
    Breast cancer (observational meta-analysis)9Low proxyHigh heterogeneity (I² high), residual confounding possible; relies on published adjusted estimates.
    BP→stroke/dementia (randomized meta-analysis)9Low proxyHeterogeneity across trials; dementia outcomes often secondary; dependence on achieved BP differences and meta-analytic models.
    Smoking cessation→spirometry (clinical trials meta-analysis)6ModerateSmall number of studies for some endpoints; very high heterogeneity (I² up to ~97%); some high-risk-of-bias studies; short follow-up.
    Habit formation→PA habit strength (behavioral RCT meta-analysis)7Moderate-lowSelf-report outcomes (response bias); BCT coding from published materials may be incomplete; heterogeneity (I²~64%).
    Ozone→diabetes (environmental observational meta-analysis)6ModerateExposure misclassification (outdoor vs personal); residual confounding; co-pollutant confounding not fully resolved; observational causal limits.
    RA-GWAS bibliometrics (bibliometric analysis)7.5Moderate-lowDatabase/language bias (WoSCC, English); gray literature underrepresented; data access restrictions limit full reproducibility.
    Network meta-analysis challenges (perspective)8Moderate-lowFocus is methodological; emphasizes protocol-registration gaps, transitivity/inconsistency issues across NMAs.
    CYP3A4 variants→brexpiprazole (in vitro kinetics)8Moderate-lowIn vitro to in vivo extrapolation limits; recombinant system may not reflect hepatic milieu/transporters; single substrate focus.
    IRT gain score metric (measurement method)8Moderate-lowModel-assumption dependence (Rasch/IRT); potential underestimation of error variances in approximation; typographical inconsistencies noted in CI reporting.
    Achilles tendon reply (comment/reply)7Moderate-lowMethodological limitations and need for more RCTs; possible publication bias; limited RCT set.
    MSC perianal fistulas comment (commentary)5Moderate-highCommentary without new data; interpretation may be biased; doesn’t constitute reanalysis.
    Xuefuzhuyu decoction TCM (systematic review of low-quality RCTs)3High proxyUnclear randomization/blinding; short follow-up; limited safety data; small single-country trials; risk of selection/performance/detection biases.
    5) What could mislead this comparison (and how to counteract)
    • Proxy risk ≠ formal RoB: the bias-risk proxy uses “scientific-quality score” from provided metadata, which may be subjective or computed differently across papers. Where a paper reports explicit uncertainty signals (e.g., I²), that’s more directly informative (e.g., breast-cancer I²≈76.5% ).
    • Observational confounding limits: some meta-analyses claim risk reductions but still rely on non-randomized exposures; residual confounding can remain (breast-cancer observational synthesis ).
    • Publication/reporting bias: even when funnel/Egger are reported non-significant in one analysis, that doesn’t eliminate bias (e.g., breast-cancer analysis notes non-significant Egger in the provided excerpt ).
    • Between-field incommensurability: comparing “bias risk” across domains (e.g., enzymology in vitro vs epidemiology vs bibliometrics) conflates different sources of uncertainty. This is why the table labels study-type and keeps uncertainties separate.
    • Model/measurement assumptions: in methodological work, the main “bias risks” are assumption violations (IRT/Rasch invariance/local independence; plus approximation limitations) .
    • Commentary vs evidence: commentaries can correctly highlight risks but are not equivalent to reanalysis; e.g., MSC commentary is interpretation-only .
    6) Counterpoint questions (what would disprove/reshape this comparison)
    • If you obtain the papers’ full RoB outputs (or GRADE/AMSTAR-NMA assessments where applicable), does the ranking based on quality-score proxy hold?
    • For the observational meta-analyses, if additional cohorts with stronger confounder control systematically shrink effect sizes toward null, does the apparent “direction” persist (e.g., breast-cancer HR≈0.84 )?
    • For the high-heterogeneity domains, if the heterogeneity drivers (disease subtype, exposure definition, outcome ascertainment) are re-modeled with better measurement equivalence, does the proxy bias risk remain moderate?
    • For in vitro work, if in vivo PK/PD and genotype associations contradict variant-specific kinetic directions, the kinetic mechanism may need revision (CYP3A4 in vitro study ).


    Feedback:    

    Updated: April 22, 2026

     Top Data Sources ExportMCP


     Analysis Wizard



    Creates a study-type summary and bias-risk proxy dashboard from the provided Wang-papers JSON, generating Plotly charts for quality-score ranking and heterogeneity where I² is present.



     Hypothesis Graveyard


    A “one-size-fits-all” explanation that low scientific-quality scores universally predict true bias is unlikely, because high-quality meta-analyses can still show large I² from real biological/outcome differences (e.g., breast-cancer I² reported high despite high quality score ).

     Science Art


    Meta-analysis: Compare the provided Bingbing Wang papers by study type and bias risk Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending